aztreonam has been researched along with Disease Models, Animal in 14 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aztreonam, ceftazidime, cefoperazone and latamoxef (moxalactam) were evaluated in a hamster model for antibiotic-associated colitis." | 7.67 | Evaluation of aztreonam, cefoperazone, latamoxef and ceftazidime in the hamster colitis model. ( Bonner, DP; Clark, JM; Fernandes, PB; Kao, CC; Sykes, RB; Weinberg, DS, 1986) |
| "The efficacy of various group antibacterial drugs: aminoglycosides, quinolones, 3rd generation cephalosporins, doxycycline, rifampicin, ampicillin and azthreonam was estimated in the treatment of experimental plague of albino mice induced by antigen complete and atypical strains of the F1- phenotype plague microbe." | 3.70 | [Characteristics of etiotropic therapy of plaque infection induced by atypical strains of F1- phenotype plaque microbe]. ( Ryzhko, IV; Samokhodkina, ED; Shcherbaniuk, AI; Tsetskhladze, NS; Tsuraeva, RI, 1998) |
| "To describe the pharmacokinetic profile of aztreonam and vancomycin hydrochloride in a clinically relevant experimental model of hemorrhagic shock and trauma." | 3.69 | Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. ( Boucher, BA; Croce, MA; Fabian, TC; McKindley, DS; Proctor, KG, 1995) |
| "Aztreonam, ceftazidime, cefoperazone and latamoxef (moxalactam) were evaluated in a hamster model for antibiotic-associated colitis." | 3.67 | Evaluation of aztreonam, cefoperazone, latamoxef and ceftazidime in the hamster colitis model. ( Bonner, DP; Clark, JM; Fernandes, PB; Kao, CC; Sykes, RB; Weinberg, DS, 1986) |
| " Pharmacokinetic (PK)/pharmacodynamic (PD) understanding of this combination is critical for optimal clinical dose selection." | 1.42 | Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. ( Bradford, PA; Eakin, AE; Harris, JJ; Kim, A; McLaughlin, RE; O'Donnell, JP; Patey, S; Singh, R; Tanudra, MA, 2015) |
| " The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection." | 1.35 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. ( Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009) |
| "Metronidazole was more potent than amoxicillin/clavulanic acid and anti-tumour necrosis factor in improving the indometacin-induced small bowel inflammation." | 1.31 | Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model. ( Ceuppens, JL; Colpaert, S; De Greef, B; Geboes, K; Liu, Z; Rutgeerts, P, 2001) |
| "In addition, combined treatments of bacterial infections should allow for a reduction in dosages of antibiotics while at the same time, achieving increased efficacy." | 1.28 | Potentiation by nonspecific immunostimulation of the efficacy of antibiotics in the treatment of experimental bacterial infections. ( Bizzini, B; Fattal-German, M, 1989) |
| "Aztreonam was bactericidal for growing bacilli in vitro and, when injected 1 and 5 hours after aerogenic exposure, provided greater than 80% protection after dosage at the level of 12." | 1.27 | Effect of aztreonam on the growth of Pasteurella multocida in the lung. ( Collins, FM, 1984) |
| "Aztreonam was the first compound to emerge that fulfilled the objectives of the program." | 1.27 | Aztreonam: the first monobactam. ( Bonner, DP; Sykes, RB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (42.86) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Gahane, AY | 1 |
| Singh, V | 1 |
| Kumar, A | 1 |
| Kumar Thakur, A | 1 |
| Singh, R | 1 |
| Kim, A | 1 |
| Tanudra, MA | 1 |
| Harris, JJ | 1 |
| McLaughlin, RE | 1 |
| Patey, S | 1 |
| O'Donnell, JP | 1 |
| Bradford, PA | 1 |
| Eakin, AE | 1 |
| Sabet, M | 1 |
| Miller, CE | 1 |
| Nolan, TG | 1 |
| Senekeo-Effenberger, K | 1 |
| Dudley, MN | 1 |
| Griffith, DC | 1 |
| Collins, FM | 1 |
| San Joaquin, VH | 1 |
| Stutman, HR | 1 |
| Marks, MI | 1 |
| Fernandes, PB | 2 |
| Bonner, DP | 3 |
| Sykes, RB | 3 |
| McKindley, DS | 1 |
| Fabian, TC | 1 |
| Boucher, BA | 1 |
| Croce, MA | 1 |
| Proctor, KG | 1 |
| Soriano, F | 1 |
| García-Corbeira, P | 1 |
| Ponte, C | 1 |
| Fernández-Roblas, R | 1 |
| Gadea, I | 1 |
| Ryzhko, IV | 1 |
| Samokhodkina, ED | 1 |
| Tsuraeva, RI | 1 |
| Shcherbaniuk, AI | 1 |
| Tsetskhladze, NS | 1 |
| Ernst, EJ | 1 |
| Hashimoto, S | 1 |
| Guglielmo, J | 1 |
| Sawa, T | 1 |
| Pittet, JF | 1 |
| Kropp, H | 1 |
| Jackson, JJ | 1 |
| Wiener-Kronish, JP | 1 |
| Colpaert, S | 1 |
| Liu, Z | 1 |
| De Greef, B | 1 |
| Rutgeerts, P | 1 |
| Ceuppens, JL | 1 |
| Geboes, K | 1 |
| Bizzini, B | 1 |
| Fattal-German, M | 1 |
| Weinberg, DS | 1 |
| Kao, CC | 1 |
| Clark, JM | 1 |
14 other studies available for aztreonam and Disease Models, Animal
| Article | Year |
|---|---|
Development of mechanism-based antibacterial synergy between Fmoc-phenylalanine hydrogel and aztreonam.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Bacterial Load; Dipeptides; Disease | 2020 |
Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lac | 2015 |
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Ani | 2009 |
Effect of aztreonam on the growth of Pasteurella multocida in the lung.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Cattle; Cattle Diseases; Disease Models, Animal; Female; | 1984 |
Hemophilus influenzae type b meningitis in infant rabbits. Pathogenesis and therapy.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Haemophilus Infections; Half-Life | 1984 |
Aztreonam: a new concept in beta-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Cricetinae; Disease Models, Animal; Drug Interactions; Gr | 1983 |
Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Female; Fluid Therapy; Hemodynami | 1995 |
Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Aztreonam; Cefazolin; Cefotaxime; Disease Models, Animal | 1996 |
[Characteristics of etiotropic therapy of plaque infection induced by atypical strains of F1- phenotype plaque microbe].
Topics: Aminoglycosides; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Ant | 1998 |
Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.
Topics: Animals; Aztreonam; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug | 1999 |
Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Anti-Inflammatory Age | 2001 |
Potentiation by nonspecific immunostimulation of the efficacy of antibiotics in the treatment of experimental bacterial infections.
Topics: Adjuvants, Immunologic; Ampicillin; Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; | 1989 |
Evaluation of aztreonam, cefoperazone, latamoxef and ceftazidime in the hamster colitis model.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; Bacterial Toxin | 1986 |
Aztreonam: the first monobactam.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Bacterial Proteins; beta-Lactamases | 1985 |